Project Grant R01HL175661
Award Date
7/15/24
Completion Date
6/30/28
Dollars Obligated
$545K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Birmingham, AL 35294, USA
Similar Awards
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $1,061,189 to support research on immune crosstalk in lung injury and fibrosis. The key objectives are: 1) studying epithelial HB-EGF regulation of fibrosis and its interaction with myeloid cells, 2) uncovering mechanisms for impaired innate immunity against gram-positive infections...
This federal Project Grant award from the National Institute of Environmental Health Sciences (NIEHS) under the Environmental Health (CFDA 93.113) program provides $527,300.00 to investigate the mechanisms underlying impaired regeneration of the alveolar epithelium and progressive fibrosis in silicosis and asbestosis. The research aims to define distinct subtypes of transitional alveolar epithelial cells, determine how specific signaling pathways prevent their differentiation into alveolar...
This $774,585 Project Grant was awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The grant supports research to investigate the mechanisms underlying the emergence and functional role of inflammatory fibroblasts in pulmonary fibrosis. Key research activities include: Comparing the timing, persistence, and fate of inflammatory fibroblasts in mouse models of pulmonary fibrosis (bleomycin, silica) versus an...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $545,400 to the Georgia Tech Research Corporation to study the role of mechanosensing in lung fibrosis. The research aims to elucidate how age-related dysregulation of focal adhesion kinase (FAK) mechanosignaling contributes to extracellular matrix remodeling, senescence, and other pathways driving idiopathic pulmonary fibrosis....
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $616,000.00 to Northwestern University to conduct research on the role of mitochondrial metabolism in alveolar epithelial cell fate. The study aims to determine whether an increased mitochondrial NADH/NAD+ ratio and activation of the integrated stress response (ISR) pathway preclude normal alveolar epithelial differentiation,...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $683,564 to The Trustees of the University of Pennsylvania to study the role of alveolar epithelial cell stress signaling in the development of pulmonary fibrosis. The project aims to determine how aberrant transitional alveolar epithelial cells contribute to fibrosis and to define the impact of the PERK-integrated stress response pathway on epithelial...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research Federal Grant Program (CFDA 93.837), provides $651,019 to the Regents of the University of Michigan to conduct research on dysfunctional epithelial repair in pulmonary fibrosis. The key focus of this 4-year project is to elucidate the factors and pathways that contribute to aberrant epithelial cell states in persistent lung fibrosis, with the goal of identifying...
This Project Grant award of $5,715,866 from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) aims to develop a novel, transformative understanding of the early pathogenesis of pulmonary fibrosis (PF) to enable new strategies for pre-clinical disease detection and prevention. The primary awardee, the Regents of the University of Michigan, leads a highly integrated program with 4 research projects and 3 supporting cores. Key objectives include using...
This federal Project Grant award, provided by the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), supports a 5-year research project to investigate the role of interleukin-6 (IL-6) signaling in promoting fibroblast resistance to apoptosis in progressive pulmonary fibrosis (PPF). The $313,632 award to National Jewish Health will enable Dr. Joseph Cooley and his team to utilize in vitro cell culture, precision-cut lung slices, and...
This $1,644,550 Cooperative Agreement awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) will support research to understand how interactions between epithelial cells, mesenchymal cells, and the extracellular matrix drive progressive fibrosis in interstitial lung diseases (ILD). The project aims to leverage spatial transcriptomics, single-cell secretion analysis, and regional proteomics to study these cellular...